Peter joined MDS Capital in 2005 as President and CEO to oversee and manage the generational change resulting from the retirement of the founding CEO. In 2007 he led the management buyout of MDS Capital and rebranding it as Lumira Ventures. Peter oversees the overall business operations of the firm and is a core part of the senior senior management team that is making new investments out of the recently closed Lumira Ventures IV and Angelini Lumira Biosciences funds, well as managing the legacy investments of our prior funds His investment focuses include growth equity, non-traditional and consumer oriented medicines, spin-outs, re-structurings and public companies. With 34 years of investment and operating experience, he has participated in building companies from start-up through to expansion and has been involved not only with companies in the life sciences sector, but also with companies in the information technology and consumer sectors. Having working as an investor, partner and mentor to highly successful management teams as well as an entrepreneur – Peter’s experience includes: partner in a buyouts partnership targeting the retail and consumer centric businesses, vice president business development for a venture capital backed drug delivery company, and an associate role at Canada’s then largest venture capital firm. He started started his career at Connaught Biosciences. Immediately prior to joining Lumira Capital, Peter was a founding partner at a merchant banking boutique. Peter holds an MBA from the Schulich School of Business, Toronto, Ontario, as well as an MSc in pathology and an honours BSc in life sciences – both from Queen’s University, Kingston, Ontario. Peter’s current board and recent board responsibilities include: Medexus, Amacathera, Exact Imaging, Edesa Biotech, the Canadian Venture Capital and Private Equity Association, CML Healthcare, Craigleith Ski Club, Spinal Kinetics, Life Sciences Ontario, Skinstore.com, Alveolus Inc., Milcom and Lumira Capital Peter joined MDS Capital in 2005 as President and CEO to oversee and manage the generational change resulting from the retirement of the founding CEO. In 2007 he led the management buyout of MDS Capital and rebranding it as Lumira Ventures. Peter oversees the overall business operations of the firm and is a core part of the senior senior management team that is making new investments out of the recently closed Lumira Ventures IV and Angelini Lumira Biosciences funds, well as managing the legacy investments of our prior funds His investment focuses include growth equity, non-traditional and consumer oriented medicines, spin-outs, re-structurings and public companies. With 34 years of investment and operating experience, he has participated in building companies from start-up through to expansion and has been involved not only with companies in the life sciences sector, but also with companies in the information technology and consumer sectors. Having working as an investor, partner and mentor to highly successful management teams as well as an entrepreneur – Peter’s experience includes: partner in a buyouts partnership targeting the retail and consumer centric businesses, vice president business development for a venture capital backed drug delivery company, and an associate role at Canada’s then largest venture capital firm. He started started his career at Connaught Biosciences. Immediately prior to joining Lumira Capital, Peter was a founding partner at a merchant banking boutique. Peter holds an MBA from the Schulich School of Business, Toronto, Ontario, as well as an MSc in pathology and an honours BSc in life sciences – both from Queen’s University, Kingston, Ontario. Peter’s current board and recent board responsibilities include: Medexus, Amacathera, Exact Imaging, Edesa Biotech, the Canadian Venture Capital and Private Equity Association, CML Healthcare, Craigleith Ski Club, Spinal Kinetics, Life Sciences Ontario, Skinstore.com, Alveolus Inc., Milcom and Lumira Capital

• 

  Managing General Partner in Lumira Ventures

  Our mission is to deliver exceptional returns for investors by investing in and helping to create value in transformative life sciences companies.